1、Click here or press enter for the accessibility optimised versionEVALUATINGRadiopharmaceuticalsClick here or press enter for the accessibility optimised versionRadio-pharmaceuticalsLight UpThe prospect of a modality that is lessconstrained by genetic mutations,whosemechanism of action invites combin

2、ationwith existing treatment categories,hasBig Pharma salivating.Radiopharmaceuticals have lit up.Strongdata from Novartis oncology drugsLutathera and Pluvicto,plus developersquest for an alternative modality with“pan-cancer”potential,has drivenmultibillion-dollar acquisitions,a$350million IPO and a

3、 flurry of VCinvestments.Bristol Myers Squibbs$4.1 billionRayzeBio purchase,Eli Lillys POINTBiopharma buy and AstraZenecas$2billion up-front deal for FusionPharmaceuticals,each with clinical-stageassets,catapult this Big Pharma trio intothe field.Eager to stay ahead,Novartis isbuying up earlier-stag

4、e assets andtechnology:on May 2,it announced a$1billion deal for Mariana Oncology and itspre-clinical pipeline.Radiopharmaceuticals Light UpExhibit 1:Recent RLT DealsDealValueDateNovartis buys Mariana Oncology$1bn upfront&up to$750m in m/sMay 2024AstraZeneca buys Fusion$2bn upfront&up to$400

5、m contingent value rightsMarch 2024Bristol Myers Squibb buys RayzeBio$4.1bnDecember 2023Eli Lilly buys POINT Biopharma$1.4bnOctober 2023Ariceum buys Theragnostics$2.5m u/f;up to$41.5m m/sJune 2023Eager to stay ahead,Novartis is buying up earlier-stage assets andtechnology:on May 2,it announced a$1 b

6、illion deal for Mariana Oncologyand its pre-clinical pipeline.See what you treatThe appeal?Radiopharmaceuticals delivertargeted radiation to cancer cells,using acancer-targeting ligand such as anantibody,peptide or small molecule todirect the radioactive isotope to the siteof interest,with minimal d